Regeneron (REGN) and Sanofi settle a lawsuit and expand antibody co‑development. Key implications for collaboration revenue, EYLEA franchise and patent risk. (2026-10-06)
Regeneron (REGN) awards long-term PSUs to CEO and CSO tied to 10-year growth goals; context on EYLEA revenue concentration, patents, collaborations, and risks.
Regeneron (REGN) creates a majority-owned subsidiary to explore non-core business; implications for EYLEA concentration, collaborations, and risk profile.
Regeneron (REGN) will record a $127M pre-tax IPR&D charge in Q2 2026, reducing reported earnings. EYLEA accounted for $7,891M (55%) of 2025 net product sales.